Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Joanna Mercado"'
Autor:
Mary Carmen Valenzano, Katherine DiGuilio, Joanna Mercado, Mimi Teter, Julie To, Brendan Ferraro, Brittany Mixson, Isabel Manley, Valerissa Baker, Beverley A Moore, Joshua Wertheimer, James M Mullin
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0133926 (2015)
The micronutrients zinc, quercetin, butyrate, indole and berberine were evaluated for their ability to induce remodeling of epithelial tight junctions (TJs) and enhance barrier integrity in the CACO-2 gastrointestinal epithelial cell culture model. A
Externí odkaz:
https://doaj.org/article/f3fdcac2b9c74a16ae3e086d87c76d4b
Autor:
Joanna Mercado, Mary Carmen Valenzano, Cameron Jeffers, Jason Sedlak, Marina K Cugliari, Eleni Papanikolaou, Jacob Clouse, Jingya Miao, Nina E Wertan, James M Mullin
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78775 (2013)
Amid an increasing number of reports in the literature concerning epithelial barrier enhancement by various nutrient compounds, there has never been a study performing side-by-side comparisons of these agents in a single epithelial model. We compare
Externí odkaz:
https://doaj.org/article/1cd0a19dcc364bdaa97b299debe03b35
Autor:
Amy E, Leader, Joanna, Mercado, Austin, Klein, Colette, Hyatt, Laura, Gross, Rachael, Brandt, Veda N, Giri
Publikováno v:
J Community Genet
Patients with prostate cancer (PCA) are increasingly being offered germline genetic testing for precision therapy, precision management, and clinical trial options. Genetic test results also have implications for family members. How men with PCA perc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49161846bfe442a4569c312da00cd0c5
https://doi.org/10.1007/s12687-022-00603-1
https://doi.org/10.1007/s12687-022-00603-1
Autor:
Nancy U. Lin, Judy E. Garber, Laura E. MacConaill, Neal I. Lindeman, Bruce E. Johnson, Randall E. Newmark, Mary-Ellen Taplin, Brian M. Wolpin, Matthew B. Yurgelun, Panagiotis A. Konstantinopoulos, Mark M. Awad, Renato Umeton, Ji Seok Kim, Melissa E. Hughes, Samantha Stokes, Sarah Kane, Anu Chittenden, Israel Gomy, Joanna Mercado, Nabihah Tayob, Jilliane Sotelo, Tianyu Li, Brittany L. Bychkovsky
Supplementary Figure from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f26e0c021c2a6e3a65e68726923c017e
https://doi.org/10.1158/1078-0432.22483952
https://doi.org/10.1158/1078-0432.22483952
Autor:
Nancy U. Lin, Judy E. Garber, Laura E. MacConaill, Neal I. Lindeman, Bruce E. Johnson, Randall E. Newmark, Mary-Ellen Taplin, Brian M. Wolpin, Matthew B. Yurgelun, Panagiotis A. Konstantinopoulos, Mark M. Awad, Renato Umeton, Ji Seok Kim, Melissa E. Hughes, Samantha Stokes, Sarah Kane, Anu Chittenden, Israel Gomy, Joanna Mercado, Nabihah Tayob, Jilliane Sotelo, Tianyu Li, Brittany L. Bychkovsky
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::051c17a541dbd14cc5b1e331436dac7d
https://doi.org/10.1158/1078-0432.22483931.v1
https://doi.org/10.1158/1078-0432.22483931.v1
Autor:
Nancy U. Lin, Judy E. Garber, Laura E. MacConaill, Neal I. Lindeman, Bruce E. Johnson, Randall E. Newmark, Mary-Ellen Taplin, Brian M. Wolpin, Matthew B. Yurgelun, Panagiotis A. Konstantinopoulos, Mark M. Awad, Renato Umeton, Ji Seok Kim, Melissa E. Hughes, Samantha Stokes, Sarah Kane, Anu Chittenden, Israel Gomy, Joanna Mercado, Nabihah Tayob, Jilliane Sotelo, Tianyu Li, Brittany L. Bychkovsky
Purpose:Tumor-only genomic testing can uncover somatic and germline pathogenic variants [pathogenic/likely pathogenic (P/LP)] in cancer predisposition genes. We describe the prevalence of P/LPs in BRCA1/2 and PALB2 (B1B2P2) across malignancies and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c0816df7ae18d46dc36bd12517df601
https://doi.org/10.1158/1078-0432.c.6531278
https://doi.org/10.1158/1078-0432.c.6531278
Autor:
Brittany L. Bychkovsky, Tianyu Li, Jilliane Sotelo, Nabihah Tayob, Joanna Mercado, Israel Gomy, Anu Chittenden, Sarah Kane, Samantha Stokes, Melissa E. Hughes, Ji Seok Kim, Renato Umeton, Mark M. Awad, Panagiotis A. Konstantinopoulos, Matthew B. Yurgelun, Brian M. Wolpin, Mary-Ellen Taplin, Randall E. Newmark, Bruce E. Johnson, Neal I. Lindeman, Laura E. MacConaill, Judy E. Garber, Nancy U. Lin
Publikováno v:
Clin Cancer Res
Purpose: Tumor-only genomic testing can uncover somatic and germline pathogenic variants [pathogenic/likely pathogenic (P/LP)] in cancer predisposition genes. We describe the prevalence of P/LPs in BRCA1/2 and PALB2 (B1B2P2) across malignancies and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6eb4a4a5c07d9317829d420b37a90c1
https://doi.org/10.1158/1078-0432.ccr-21-2861
https://doi.org/10.1158/1078-0432.ccr-21-2861
Publikováno v:
Journal of genetic counselingREFERENCES. 31(3)
Genetic counselors, like many other healthcare providers, play a vital role in genomic health care. As a profession, we, along with our colleagues and students, have recognized the need to improve and incorporate diversity, equity, inclusion, and jus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec74b1405ae7d2351f9344613ebd0e8a
https://pubmed.ncbi.nlm.nih.gov/35006622
https://pubmed.ncbi.nlm.nih.gov/35006622
Autor:
Laura E. MacConaill, Judy Garber, Melissa E. Hughes, Bruce E. Johnson, Ji Seok Kim, Israel Gomy, Joanna Mercado, Mary-Ellen Taplin, Sarah R. Kane, Tianyu Li, Brittany L. Bychkovsky, Neal I. Lindeman, Panagiotis A. Konstantinopoulos, Mark M. Awad, Samantha Stokes, Nabihah Tayob, Jilliane Sotelo, Brian M. Wolpin, Nan Lin, Anu Chittenden
Publikováno v:
Journal of Clinical Oncology. 39:10528-10528
10528 Background: Tumor-genomic testing is increasingly used to guide treatment decisions in cancer patients. Although tumor-only testing cannot definitively distinguish between germline versus somatic alterations, the identification of pathogenic or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33581e72db0e8953fc97e70aa9614875
https://doi.org/10.1200/jco.2021.39.15_suppl.10528
https://doi.org/10.1200/jco.2021.39.15_suppl.10528
Autor:
Jill E. Stopfer, Lindsay Kipnis, Sara Pirzadeh-Miller, ProGen Study Team, Kevin D. Courtney, Samantha Culver, Diane R. Koeller, Jill S. Dolinsky, Donna Rachel Vatnick, Virginia Speare, Mary-Ellen Taplin, Judy Garber, Theodora S. Ross, Nancie Petrucelli, Huma Q. Rana, Rebecca Silver, Elisabeth I. Heath, Rebecca Gelman, Michelle Weitz, Brian Reys, Joanna Mercado
Publikováno v:
Journal of Clinical Oncology. 38:1507-1507
1507 Background: Approximately 10% of men with advanced prostate cancer (PC) have pathogenic/likely pathogenic variants (PV) in cancer susceptibility genes and their identification may lead to targeted therapy. Genetic testing (GT) can also guide can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00509a50841c13dd7b9ca3f0b87da911
https://doi.org/10.1200/jco.2020.38.15_suppl.1507
https://doi.org/10.1200/jco.2020.38.15_suppl.1507